Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our API


BioCardia, Inc.(Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced today that Chief Executive Officer, Peter Altman, will participate in a fireside chat as well as one on one meetings at the upcoming BTIG Virtual Biotechnology Conference being held August 9-10, 2021.


GlobeNewswire Inc | Aug 4, 2021 08:00AM EDT

August 04, 2021

SAN CARLOS, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- BioCardia, Inc.(Nasdaq: BCDA), a leader in the development of comprehensive solutions for cardiovascular and pulmonary cell based therapies, announced today that Chief Executive Officer, Peter Altman, will participate in a fireside chat as well as one on one meetings at the upcoming BTIG Virtual Biotechnology Conference being held August 9-10, 2021.

Fireside Chat Event Details:

BTIG Virtual Biotechnology ConferenceDate: Tuesday, August 10, 2021Time: 3:30-3:55 pm ET / 12:30-12:55 PT

Click here to register.

For those unable to attend, a replay of the presentation will be available until the end of the day Tuesday, August 10, 2021 on the BTIG conference website. You must be a BTIG client to attend and access the replay.

About BioCardia

BioCardia, Inc., headquartered in San Carlos, California, is developing regenerative biologic therapies to treat cardiovascular and pulmonary disease. CardiAMP autologous and NK1R+ allogeneic cell therapies are the Companys biotherapeutic product candidates in clinical development. The Company's current products include the Helix transendocardial delivery system, the Morph steerable guide and sheath catheter portfolio and the AVANCE steerable introducer family. BioCardia also partners with other biotherapeutic companies to provide its Helix systems and development support to their programs studying therapies for the treatment of heart failure, chronic myocardial ischemia and acute myocardial infarction. For more information, visitwww.BioCardia.com.

INVESTOR CONTACT:David McClung, Chief Financial Officerinvestors@BioCardia.com(650) 226-0120

MEDIA CONTACT:Anne Laluc, MarketingEmail:alaluc@biocardia.comPhone: 650-226-0120







Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC